Category Lobbying

Academies’ Group Urges EU Harmonisation Of Rules On Inventorship, Patenting

A high-level group of academic experts in intellectual property rights and innovation in the European Union has released a statement highlighting the rise in inventions due to international research and development and says EU regulations on inventorship, assignment and patent filing should be assessed for harmonisation and reducing complexity.

Patenting Artificial Intelligence Might Hamper Progress, EFF Says

The Electronic Frontier Foundation launched a project last year to measure progress in artificial intelligence innovations and understand the legal, political, and technical issues potentially raised by those inventions. Some eight months later, the project has tracked rapid progress of those technologies, in particular in machine learning. According to the foundation, patents might be hampering the progress of artificial intelligence, and with the risk of patent trolls claiming rights on patents on machine learning systems.

Indian Pharma Industry Disputes US Industry IP Index

The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving".

US Industry Index Makes Case For Strong IP Protection Worldwide

The United States Chamber of Commerce sixth annual International IP Index, released yesterday, highlights positive developments in 50 economies to better protect intellectual property rights so as to reward creativity and innovation. But it also takes aim at practices the US industry group still sees as counterproductive.

On IPR, Major US Trading Partners In Firing Line Of US Industry, While Cancer Patients Ask For Access

Every year at this time, the Office of the United States Trade Representative collects comments from stakeholders for its review of how well US trading partners are behaving when it comes to protecting and enforcing the intellectual property rights of US companies. Pharmaceutical companies and an alliance of rights holding industries came prepared with a list of countries to be put on special watch lists, including Canada, Brazil, India, Malaysia, and Switzerland. A patient group, on the other hand, asked that trade interests not supersede access to medicines worldwide.

“We Must Engage With Industry” – WHO Director Explains Limits On Lobbyists

The engagement of actors such as industry, civil society, philanthropy and academia with the World Health Organization has been a subject of controversy, with some of those actors being potentially able to influence the work of the organisation. A framework for engagement with those stakeholders was agreed two years ago. At last week's Executive Board meeting, the new WHO director general explained that engagement with those actors, and notably industry, is worth the risk, which he said can be managed.